NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis $0.18 +0.02 (+11.88%) As of 03:26 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bio-Path Stock (NASDAQ:BPTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bio-Path alerts:Sign Up Key Stats Today's Range$0.15▼$0.1850-Day Range$0.14▼$0.8552-Week Range$0.12▼$7.67Volume31,830 shsAverage Volume1.60 million shsMarket Capitalization$1.49 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Read More… Remove Ads Bio-Path Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBPTH MarketRank™: Bio-Path scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBio-Path has received no research coverage in the past 90 days.Read more about Bio-Path's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($3.34) to ($1.55) per share.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bio-Path's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BPTH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BPTH. News and Social Media1.8 / 5News Sentiment0.29 News SentimentBio-Path has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Bio-Path this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.72% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions.Read more about Bio-Path's insider trading history. Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address BPTH Stock News HeadlinesRoth Capital Has Optimistic Outlook of Bio-Path Q1 EarningsApril 4 at 1:51 AM | americanbankingnews.comBio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.comApril 3 at 2:09 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Bio-Path price target lowered to $9 from $12 at Roth MKMMarch 31, 2025 | markets.businessinsider.comBio-Path reports FY24 EPS ($4.12) vs ($33.63) last yearMarch 29, 2025 | markets.businessinsider.comBio-Path Holdings Reports Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comBio-Path (NASDAQ:BPTH) Now Covered by StockNews.comMarch 26, 2025 | americanbankingnews.comBio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes PatientsMarch 18, 2025 | globenewswire.comSee More Headlines BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed this year? Bio-Path's stock was trading at $1.16 at the beginning of 2025. Since then, BPTH stock has decreased by 87.0% and is now trading at $0.1510. View the best growth stocks for 2025 here. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its quarterly earnings results on Thursday, August, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.54) by $0.38. When did Bio-Path's stock split? Bio-Path shares reverse split on Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings8/15/2024Today4/04/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPTH CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+11,073.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,842.40% Return on Assets-337.48% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.25Miscellaneous Outstanding Shares8,308,000Free Float5,726,000Market Cap$1.49 million OptionableOptionable Beta0.13 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:BPTH) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.